Japanese Encephalitis Virus In Northern Australia And Papua New Guinea:its Ecology And Risk To Australia.
Funder
National Health and Medical Research Council
Funding Amount
$292,045.00
Summary
Japanese encephalitis (JE) virus is a mosquito-transmitted virus of Asia. Infection causes clinical disease in about 1 in 50 people infected, and of these, about 25% will die from a fatal encephalitis (inflammation of the brain), and a further 50% will have lifelong severe disabilities. There are over 50,000 cases annually in Asia, with about 12,000 fatalities. However, many more cases may go unrecognised. The virus normally circulates between mosquitoes and water birds and between mosquitoes an ....Japanese encephalitis (JE) virus is a mosquito-transmitted virus of Asia. Infection causes clinical disease in about 1 in 50 people infected, and of these, about 25% will die from a fatal encephalitis (inflammation of the brain), and a further 50% will have lifelong severe disabilities. There are over 50,000 cases annually in Asia, with about 12,000 fatalities. However, many more cases may go unrecognised. The virus normally circulates between mosquitoes and water birds and between mosquitoes and pigs. The World Health Organization has recognised JE as one of the most important mosquito-borne viruses because of its propensity to spread and to colonise new areas. The virus first appeared in the Torres Strait of northern Australia in 1995, causing three clinical cases of whom 2 died. This was unexpected as the nearest known focus of virus activity was in Bali, over 3000km away. The virus returned again in 1998, with a further case in the Torres Strait and the first case to occur on mainland Australia in Cape York. Both of these patients recovered. We have shown that the virus is established in Papua New Guinea (PNG), where it is spreading rapidly, and our results suggest that PNG was the source of the virus causing the outbreaks in 1995 and 1998. This project is aimed at finding out more about JE virus in PNG, particularly as it relates to spread into northern Australia. The project also seeks to investigate the potential mosquito and animal hosts in Australia that might be involved if the virus becomes established in our wildlife in Cape York. Australia is already known to have suitable mosquito vector species and suitable animal hosts in water birds and feral pigs, but the ecology is not yet understood. Thus the overall aim is to provide information on which a sound risk assessment can be based.Read moreRead less
Role Of Toll-like Receptor 7 In Rhinovirus-induced Asthma Exacerbation
Funder
National Health and Medical Research Council
Funding Amount
$697,248.00
Summary
One third of the annual asthma-related health care expenditure may be attributable to asthma-related hospitalisations. Even mild asthmatics experience severe exacerbations at a rate of almost one per year1 and those attacks can be fatal. Rhinovirus (RV) causes the majority of asthma exacerbations which may be linked to an impaired antiviral interferon (IFN) response in asthmatics. RV is sensed by Toll-like receptor (TLR) 7, but the role of this innate host defence pathway in regulating antiviral
Asthma causes wheeze and shortness of breath via airway narrowing, with asthma attacks commonly caused by virus infections. We plan to investigate how airway narrowing during an asthma attack decreases the body’s ability to fight off a viral infection, causing prolonged infection, worse asthma symptoms, more airway inflammation and long-term damage within the airways. We will attempt to use current and novel treatments to reverse these problems, and improve treatment for asthma.
Effect Of Anti-IgE Antibody On Immune System Responses And Short-term Outcome In Acute Asthma In Children
Funder
National Health and Medical Research Council
Funding Amount
$571,752.00
Summary
We plan to undertake a randomised, double-blind, placebo-controlled, clinical trial of anti-IgE antibody given at the time of an acute attack of asthma in children aged 6-12 years. The idea for this arose from our own novel data – IgE levels increase with the most common infection causing acute asthma. Given evidence the virus uses IgE to cause inflammation, giving anti-IgE during the attack should reduce the severity of the attack and produce a new, effective treatment for acute asthma.
First-in-human Evaluation Of A Novel Immunobiotic To Prevent Respiratory Infection
Funder
National Health and Medical Research Council
Funding Amount
$1,180,080.00
Summary
Respiratory infections are a leading cause of death and illness throughout the world. We have discovered a 'friendly' bacteria that can be applied up the nose to prevent ear infections and the 'flu in mice. We will now test this novel therapy in humans to check it is safe and that it stimulates the human immune system in the same way that it does in mice. This will provide essential information to conduct clinical trials, with the aim to produce a medicine that prevents respiratory infections.